Real-World Bleeding Risk among Non-Valvular Atrial Fibrillation (NVAF) Patients Prescribed Apixaban, Dabigatran, Rivaroxaban and Warfarin: Analysis of Electronic Health Records
Clinical and Demographic Characteristics According to Dosage among Non-Valvular Atrial Fibrillation Patients Newly Initiated on Novel Oral Anticoagulants
Characteristics of Patients Initiating Oral Anticoagulant Therapy for Management of Non-Valvular Atrial Fibrillation (NVAF)
Patterns of Anticoagulant Use and Rates of Recurrence Among Patients with Incident Venothromboembolism Managed in US Hospitals: A Multi-Center Electronic Health Record Study
All-Cause Healthcare Resource Utilization and Associated Medical Costs Among Newly Diagnosed Non-Valvular Atrial Fibrillation Patients Treated with Dabigatran or Warfarin Within Integrated Healthcare Delivery Networks
Annual Ischemic and Hemorrhagic Stroke Costs in an Atrial Fibrillation Population from a Health Plan Perspective
